May 16, 2025

Drug-Drug Interaction Module—FDA-Label Powered, Terminal-Ready—Now Live in All Open Models

Product News | Published: May 16, 2025

news image

PGxAI has released a new Drug-Drug Interaction (DDI) engine that mines structured information directly from FDA prescription-label sections. The module screens any two (or more) compounds for clinically significant interactions and delivers risk-tiered guidance in real time. Even the open, terminal-only versions of our models now support instant DDI queries—simply load the CLI, enter drug names, and receive evidence-linked warnings in under a second. Enterprise users can enable the same logic via our REST API for seamless EHR integration.

Ready for deeper integration or high-throughput analysis? Reach out via our contact form—we’re here to help.

Success Stories

Serving Every Stakeholder in Healthcare

AI & Multi-Omics in Pharmacogenomics: PGxAI’s New Review

PGxAI Unveils Betelgeuse — New AI Model for Real-Time Clinical Outcome Analysis and Adaptive Recommendations

Burns C. Blaxall, PhD, FACC, FAHA, Joins PGxAI as President & Chief Business Officer

Upload Your Own Genetic Data: Instant Drug-Sensitivity Insights Now in All Base Models

Bruce Broussard, Former Humana CEO, Joins PGxAI as Advisor for Reimbursement Strategy

Drug-Drug Interaction Module—FDA-Label Powered, Terminal-Ready—Now Live in All Open Models

PGxAI Unveils AI-Driven Genetic Tool to Personalize GLP-1 Drugs Including Ozempic®

PGxAI Debuts Deneb, an AI Model Revolutionizing Drug Development for Biopharma

Automated Phenoconversion Arrives: Real-Time, Context-Aware Drug-Response Scoring in Every Base Model

PGxAI Debuts Vega, an AI Model Set to Disrupt Precision Medicine

Revolutionizing Precision Medicine: PGxAI Raises $1.5 Million in Funding for AI-Powered Pharmacogenetics Platform

The Ventures Award: The World's Premier Stage for Startup Excellence

PGxAI Launches Sirius, an AI‑Powered Pharmacogenetics Model

IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration